What’s New with Innocoll?

Innocoll Announces Strategic Investment from Hillhouse Investment

Innocoll Announces Publication of Positive Results from Pivotal Clinical Trial of POSIMIR in Arthroscopic Subacromial Decompression

Innocoll Announces Positive Topline Results for XARACOLL^® (bupivacaine hydrochloride) Implant in a Phase 3 Study to Support Expanded Use

Innocoll Announces Co-Promotion Agreement for Hernia Product Portfolio

Innocoll Announces Successful Completion of Debt Refinancing

DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR^® (Bupivacaine Solution)

Innocoll Biotherapeutics plc Announces First Patients In Phase 3 Clinical Trials for Label Expansion of Xaracoll^® (bupivacaine hydrochloride) Implant

Anthony Galdi Appointed Chief Commercial Officer of Innocoll

Louis Pascarella Appointed Chief Executive Officer of Innocoll

Innocoll Announces Commercial Launch of XARACOLL^® (bupivacaine HCI) implant, a Non-opioid, Drug-device Treatment Option for Acute Postsurgical Pain Relief for up to 24 Hours Following Open Inguinal Hernia Repair in Adults